La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Tianjin Chase Sun PharmaceuticalLtd Croissance future
Future contrôle des critères 1/6
Tianjin Chase Sun PharmaceuticalLtd is forecast to grow earnings and revenue by 16.8% and 6.5% per annum respectively. EPS is expected to grow by 16.3% per annum. Return on equity is forecast to be 6% in 3 years.
Informations clés
16.8%
Taux de croissance des bénéfices
16.3%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 18.8% |
Taux de croissance des recettes | 6.5% |
Rendement futur des capitaux propres | 6.0% |
Couverture par les analystes | Low |
Dernière mise à jour | 17 May 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well
Aug 02There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings
Jun 12Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03
May 22This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts
May 21Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 04Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 7,083 | 664 | N/A | 629 | 1 |
12/31/2025 | 6,511 | 557 | N/A | 431 | 1 |
12/31/2024 | 6,194 | 533 | N/A | 715 | 1 |
3/31/2024 | 5,913 | 389 | 980 | 1,309 | N/A |
12/31/2023 | 6,109 | 507 | 1,183 | 1,530 | N/A |
9/30/2023 | 6,672 | 663 | 1,112 | 1,485 | N/A |
6/30/2023 | 6,762 | 617 | 382 | 911 | N/A |
3/31/2023 | 6,577 | 561 | 269 | 928 | N/A |
1/1/2023 | 6,650 | 624 | -25 | 745 | N/A |
9/30/2022 | 7,084 | 521 | -538 | 262 | N/A |
6/30/2022 | 7,496 | 602 | -258 | 497 | N/A |
3/31/2022 | 7,764 | 732 | -317 | 418 | N/A |
12/31/2021 | 7,671 | 687 | -286 | 392 | N/A |
9/30/2021 | 7,266 | 611 | 111 | 717 | N/A |
6/30/2021 | 7,192 | 667 | -173 | 395 | N/A |
3/31/2021 | 7,001 | 657 | -162 | 364 | N/A |
12/31/2020 | 6,488 | 573 | -367 | 197 | N/A |
9/30/2020 | 6,109 | 485 | -753 | -148 | N/A |
6/30/2020 | 5,497 | 396 | -563 | 100 | N/A |
3/31/2020 | 5,085 | 337 | -519 | 149 | N/A |
12/31/2019 | 5,003 | 403 | -375 | 216 | N/A |
9/30/2019 | 4,796 | 264 | -221 | 247 | N/A |
6/30/2019 | 4,548 | 216 | -253 | 147 | N/A |
3/31/2019 | 4,303 | 219 | -101 | 225 | N/A |
12/31/2018 | 4,224 | 211 | 93 | 388 | N/A |
9/30/2018 | 4,015 | 463 | 297 | 593 | N/A |
6/30/2018 | 3,894 | 514 | 529 | 805 | N/A |
3/31/2018 | 3,605 | 485 | 557 | 865 | N/A |
12/31/2017 | 3,374 | 451 | N/A | 742 | N/A |
9/30/2017 | 3,543 | 633 | N/A | 610 | N/A |
6/30/2017 | 3,564 | 630 | N/A | 590 | N/A |
3/31/2017 | 3,743 | 666 | N/A | 472 | N/A |
12/31/2016 | 3,867 | 659 | N/A | 448 | N/A |
9/30/2016 | 3,722 | 582 | N/A | 362 | N/A |
6/30/2016 | 3,635 | 599 | N/A | 251 | N/A |
3/31/2016 | 3,596 | 572 | N/A | 108 | N/A |
12/31/2015 | 3,348 | 535 | N/A | 121 | N/A |
9/30/2015 | 3,187 | 541 | N/A | 193 | N/A |
6/30/2015 | 3,076 | 474 | N/A | 115 | N/A |
3/31/2015 | 2,969 | 452 | N/A | 220 | N/A |
12/31/2014 | 2,864 | 447 | N/A | 150 | N/A |
9/30/2014 | 2,681 | 421 | N/A | 105 | N/A |
6/30/2014 | 2,405 | 395 | N/A | 110 | N/A |
3/31/2014 | 2,201 | 362 | N/A | 93 | N/A |
12/31/2013 | 2,097 | 340 | N/A | 144 | N/A |
9/30/2013 | 1,862 | 308 | N/A | 148 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 300026's forecast earnings growth (16.8% per year) is above the savings rate (2.9%).
Bénéfices vs marché: 300026's earnings (16.8% per year) are forecast to grow slower than the CN market (21.9% per year).
Croissance élevée des bénéfices: 300026's earnings are forecast to grow, but not significantly.
Chiffre d'affaires vs marché: 300026's revenue (6.5% per year) is forecast to grow slower than the CN market (13.4% per year).
Croissance élevée des revenus: 300026's revenue (6.5% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 300026's Return on Equity is forecast to be low in 3 years time (6%).